Skye Bioscience, INC 10-Q quarterly reports

Skye Bioscience terminates nimacimab R&D, pauses clinical trials, and focuses on a proposed acquisition of Redx Pharma, while facing ongoing financial and listing challenges.

Skye Bioscience reports Q1 2026 financial results, detailing progress and challenges in nimacimab development, alongside Nasdaq listing concerns and ongoing litigation.

Skye Bioscience's Q3 report reveals mixed Phase 2a results for nimacimab, with monotherapy failing its primary endpoint but combination with semaglutide showing significant weight loss and improved outcomes.

Skye Bioscience reported a significant increase in net loss for Q2 2025 driven by higher research and development expenses for its lead obesity drug candidate, nimacimab, while maintaining sufficient cash for the next 12 months.

Skye Bioscience continues to advance its clinical program for nimacimab, a CB1 receptor-targeting antibody, while reporting a net loss of $11.1 million for the first quarter of 2025.

Skye Bioscience reported its Q3 2024 financial results, highlighted by a significant increase in cash reserves and the advancement of its Phase 2 clinical trial for nimacimab, its obesity treatment candidate.

Skye Bioscience reports a net loss of $12.9 million for the first six months of 2024, while strategically shifting focus to its obesity program and away from its glaucoma program.

Skye Bioscience reports a significant increase in cash reserves following two successful PIPE financings, enabling the company to advance its clinical programs for glaucoma and obesity.